Monopar Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.7%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$2.90next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investments Quarterly137.5MTarget: Sufficient to fund operations at least through December 31, 2027
Quarterly Net Loss Quarterly-3.9M
Quarterly Research and Development (R&D) Expenses Quarterly3.5M
Watch Items
- ALXN1840 New Drug Application (NDA) Submission for Wilson DiseaseTrigger: Submission to the FDA planned for mid-2026Action: Monitor official press releases and SEC filings for confirmation of the NDA submission and subsequent FDA acceptance.
- MNPR-101-Zr Phase 1 Clinical Trial ProgressTrigger: Active and recruiting for diagnostic imaging in advanced solid cancersAction: Track patient enrollment updates and preliminary imaging/dosimetry data presentations.
- MNPR-101-Lu Phase 1a Clinical Trial ProgressTrigger: Active and recruiting for therapeutic treatment of advanced solid cancersAction: Evaluate safety, tolerability, and initial efficacy signals from the escalating dose cohorts.
Research as of 19 Jun 2026